[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343095-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343095-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","assessing-sarcopenia-in-advanced-stage-ovarian-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-case-series","Assessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy - A Case Series","","Objectives: In ovarian and other cancers, low muscle mass and density correlate with worse clinical outcomes, yet screening for cancer-related sarcopenia is not routinely performed. This case series evaluates how the EWGSOP2 framework applies to sarcopenia assessment in six ovarian cancer patients receiving neoadjuvant chemotherapy. Methods: Sarcopenia risk was screened with SARC-F, muscle strength measured by handgrip and five-times sit-to-stand tests, muscle mass by skeletal muscle index on CT, and physical performance by 4-m gait speed. Results: No participants met SARC-F “at risk” criteria; two met EWGSOP2 severe criteria and five were sarcopenic by muscle mass alone.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/assessing-sarcopenia-in-advanced-stage-ovarian-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-case-series/343095/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/assessing-sarcopenia-in-advanced-stage-ovarian-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-case-series/343095.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of this case series?","Question",{"text":63,"@type":64},"To explore application of the EWGSOP2 algorithm for assessing sarcopenia in six patients with advanced-stage ovarian cancer receiving neoadjuvant chemotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the study assess sarcopenia risk and the key diagnostic components?",{"text":68,"@type":64},"It used SARC-F for risk (≥4 points), handgrip strength and five-times sit-to-stand for muscle strength, skeletal muscle index on CT for muscle mass, and 4-m gait speed for physical performance.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings regarding EWGSOP2 classification?",{"text":72,"@type":64},"None were identified as “at risk” by SARC-F; two met EWGSOP2 severe criteria (low strength, mass, and physical performance), while five met sarcopenia based on muscle mass alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343095,1790149228,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Reports  \nCASE SERIES  OPEN ACCESS   \nAssessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy:  \nA Case Series  \nChristelle Schofield1,2  | Dennis R. Taaffe1,2 | Robert U. Newton1,2 | Daniel A. Galvão1,2 | Paul A. Cohen3,4 | Jin-Soo Kim1,2 | Tarek Meniawy2,3,4,5 | Carolyn Peddle-McIntyre1,2  \n1Exercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia | 2School of Medical and Health Sciences,  \nEdith Cowan University, Joondalup, Western Australia, Australia | 3School of Medicine, University of Western Australia, Crawley, Western Australia, Australia | 4St John of God Hospital, Subiaco, Western Australia, Australia | 5Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia Correspondence: Christelle Schofield ([c.schofield@ecu.edu.au](c.schofield@ecu.edu.au))  \nReceived: 13 March 2024 | Revised: 17 July 2024 | Accepted: 19 July 2024  \nFunding: C.S. was financially supported by an Edith Cowan University Ph.D. Scholarship, Australian Government Research Training Program Scholarship, and Western Australian Cancer Council Ph.D. Top-up Scholarship.  \nKeywords: muscle mass | muscle strength | ovarian cancer | sarcopenia  \nABSTRACT  \nObjectives: In ovarian and other cancers, low muscle mass and density are associated with poorer clinical outcomes. However, screening for cancer-related sarcopenia (typically defined as low muscle mass) is not routinely conducted. The European Working Group on Sarcopenia in Older People (EWGSOP) recommends an algorithm for sarcopenia screening and diagnosis in clinical settings, with sarcopenia based on muscle strength and mass, and severity on physical performance. We explored the application of the EWGSOP2 algorithm to assess sarcopenia in six ovarian cancer patients receiving neoadjuvant chemotherapy.  \nMethods: We assessed sarcopenia risk with the SARC-F screening questionnaire (at risk ≥4 points), muscle strength with ahandgrip strength test (cut point \u003C16 kg) and five times sit-to-stand test (cut point >15s), muscle mass by skeletal muscle index (SMI in cm2/m2 from a single computed tomography [CT] image; cut point \u003C38.5 cm2/m2), and physical performance with a 4-m gait speed test (cut point ≤0.8m/s) .  \nResults: Of six participants, none were identified as “at risk” for sarcopenia based on SARC-F scores. Two participants were severely sarcopenic based on EWGSOP2 criteria (had low muscle strength, mass, and physical performance), and five participants were sarcopenic based on muscle mass only.  \nDiscussion: Ovarian cancer patients with low muscle mass during neoadjuvant chemotherapy may not be identified as sarcopenic based on the EWGSOP2 diagnostic algorithm. While lacking a universally accepted definition for cancer-related sarcopenia and cancer-specific recommendations for the screening, diagnosis, and treatment of sarcopenia, ovarian cancer clinicians should focus on the diagnosis and treatment of low muscle mass and density.  \n1 | Introduction  \nSarcopenia is “a progressive and generalized skeletal muscle disorder” associated with an increased risk of physical disability  \nand mortality [1] . Although sarcopenia is primarily a condition associated with aging, it is often related to secondary factors such as physical inactivity, malnutrition, and disease such as cancer [2] . Generally, both low muscle mass and low muscle  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.  \nCancer Reports, 2024; 7:e2155  \n[https://doi.org/10.1002/cnr2.2155](https://doi.org/10.1002/cnr2.2155)  \n1 of 7  \nfunction (low muscle strength and/or impaired physical function) are required for the definition of sarcopenia [1, 3–6] . In 2018, the European Working Group on Sarcopenia in Older Peo","cbCaia22ADCZq8Y8","https://ap.wps.com/l/cbCaia22ADCZq8Y8","pdf",1569916,"English","# Introduction\n# Methods\n# Results\n# Discussion","[{\"question\":\"What was the main objective of this case series?\",\"answer\":\"To explore application of the EWGSOP2 algorithm for assessing sarcopenia in six patients with advanced-stage ovarian cancer receiving neoadjuvant chemotherapy.\"},{\"question\":\"How did the study assess sarcopenia risk and the key diagnostic components?\",\"answer\":\"It used SARC-F for risk (≥4 points), handgrip strength and five-times sit-to-stand for muscle strength, skeletal muscle index on CT for muscle mass, and 4-m gait speed for physical performance.\"},{\"question\":\"What were the key findings regarding EWGSOP2 classification?\",\"answer\":\"None were identified as “at risk” by SARC-F; two met EWGSOP2 severe criteria (low strength, mass, and physical performance), while five met sarcopenia based on muscle mass alone.\"}]","Assessing Sarcopenia in Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy - A Case Series | PDF",1790049841,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ad325b12866376a5a8c872cd859960e.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df2d8eb13aa5cc5e205d667b58c5ff09.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43e1f8a2ce18548cc9d3a4d34d7feebb.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8511dee7832494da296c175df6fb794c.webp",980,1287]